e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Novel therapeutic targets and disease markers in pulmonary pathology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G
A. Csanadi, M. E. Zeller, A. Miczak, T. Rose, T. Bizebard, V. R. Kaberdin (Vienna, Austria; Szeged, Hungary; Paris, France)
Source:
Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology
Session:
Novel therapeutic targets and disease markers in pulmonary pathology
Session type:
Oral Presentation
Number:
404
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Csanadi, M. E. Zeller, A. Miczak, T. Rose, T. Bizebard, V. R. Kaberdin (Vienna, Austria; Szeged, Hungary; Paris, France). Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G. Eur Respir J 2007; 30: Suppl. 51, 404
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Towards new antituberculotic targets: biochemical characterisation of mycobacterial RNase E/G
Source: Eur Respir Rev 2008; 17: 76-77
Year: 2008
Comparative mycobacterial genomics as a tool for drug target and antigen discovery
Source: Eur Respir J 2002; 20: 78S-86S
Year: 2002
Molecular epidemiology of tuberculosis
Source: Eur Respir J 2002; 20: 54S-65S
Year: 2002
Detection of isoniazid or rifampin resistant
Mycobacterium tuberculosis
in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Comparative analysis of detection of Mycobacterium tuberculosis and rifampin resistance determination through microbiological and molecular genetics methods for pulmonary tuberculosis patients with presence or absence of sputum
Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Year: 2012
Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods
Source: Eur Respir J, 51 (5) 1702189; 10.1183/13993003.02189-2017
Year: 2018
Novel NTM treatments and approaches, repurposed to bacteriophages
Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment
Year: 2021
The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation
Source: Virtual Congress 2020 – Tuberculosis: part 2
Year: 2020
Determination of drug susceptibility of
Mycobacterium tuberculosis
through mycolic acid analysis with HPLC technique - comparison to the conventional methods
Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities
Year: 2005
Standardised PCR-based molecular epidemiology of tuberculosis
Source: Eur Respir J 2008; 31: 1077-1084
Year: 2008
Molecular epidemiology, drug resistance, and treatment of tuberculosis in Germany: preliminary results
Source: Eur Respir J 2003; 22: Suppl. 45, 485s
Year: 2003
Efficiency of molecular methods for epidemiological investigation in tuberculosis (TB)
Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features
Year: 2012
Quantitative membrane proteomics reveals new functions ofCD13 in mycobacterium tuberculosis infection
Source: International Congress 2015 – Biomarkers in TB: immunology and physiology
Year: 2015
Improved tracking of nosocomial transmission of multidrug resistant
M. tuberculosis
with a novel T cell-based test
Source: Eur Respir J 2003; 22: Suppl. 45, 167s
Year: 2003
Traditional and molecular diagnosis of tuberculosis and atypical mycobacteria
Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Year: 2004
A fully molecular drug sensitivity pattern for M.tuberculosis complex: what is available today and what is in the pipeline
Source: International Congress 2017 – How to manage difficult tuberculosis cases: diagnosis and treatment
Year: 2017
First experience with novel molecular diagnostic method for detection of
M. tuberculosis
and rifampicin resistance
Source: Annual Congress 2011 - Tuberculosis: from bench to bedside
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept